First Trust Nasdaq Pharmaceuticals ETF
FTXH
19 hedge funds and large institutions have $7.04M invested in First Trust Nasdaq Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
51% more capital inflows, than outflows
Capital inflows: $466K | Capital outflows: $309K
6% more funds holding
Funds holding: 18 → 19 (+1)
1.03% more ownership
Funds ownership: 43.84% → 44.87% (+1%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$219K |
| 2 |
SC
Steph & Co
Marinette,
Wisconsin
|
+$136K |
| 3 |
AIP
Ameritas Investment Partners
Lincoln,
Nebraska
|
+$41.4K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$27.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$137K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
-$57K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$46.6K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$44.9K |
| 5 |
Goldman Sachs
New York
|
-$13.2K |
FTXH Hedge Fund Activity: Q3 2025 in Review
19 of the 7,647 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2025, worth a combined $7.04M — up 14% from $6.18M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new FTXH positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Stratos Wealth Partners, opening a new position worth an estimated $219K. The largest seller was LPL Financial, cutting an estimated $137K.
- 19 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2025, up from 18 in Q2 2025.
- Funds reported $7.04M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2025, up 14% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2025 and 1 closed out, a net change of +1 holder.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2025 was Stratos Wealth Partners, an estimated $219K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2025 was LPL Financial, an estimated $137K sold.
Based on aggregated 13F filings for Q3 2025.